Search - tctmd.com

Displaying 1 - 20 of 22

Sort: Relevancy | Date

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2024

Caitlin E. Cox

December 31, 2024

News Daily News

Top General Cardiology and Prevention News of 2024

Caitlin E. Cox

December 30, 2024

News Daily News

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

Yael L. Maxwell

December 13, 2024

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2024

Shelley Wood

December 03, 2024

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News AHA 2024

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

Shelley Wood

November 14, 2024

News Daily News

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Michael O'Riordan

November 13, 2024

News Daily News

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Michael O'Riordan

October 14, 2024

News Conference News ESC 2024

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Caitlin E. Cox

August 31, 2024

News Daily News

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

Yael L. Maxwell

August 19, 2024

News Opinion CV Team Dispatch

August 2024 Dispatch for the CV Team

L.A. McKeown

August 01, 2024

News Conference News ACC 2024

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

Yael L. Maxwell

July 03, 2024

News Daily News

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

Yael L. Maxwell

June 17, 2024

News Conference News NY Valves 2024

AV Block Common After Transcatheter Tricuspid Valve Replacement for TR

Michael O'Riordan

June 07, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Yael L. Maxwell

April 09, 2024

News Conference News ACC 2024

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

Todd Neale

March 27, 2024

News Daily News

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Michael O'Riordan

February 27, 2024

News Daily News

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Yael L. Maxwell

February 15, 2024

Podcast TCTMD Talking Points

Lepodisiran Phase I Trial

February 07, 2024

Advertisement

TCTMD’s Top 10 Most Popular Stories for December 2024

Top General Cardiology and Prevention News of 2024

Lp(a) Can Vary Over Time in ASCVD Patients With High Baseline Levels: OCEAN(a)-DOSE

TCTMD’s Top 10 Most Popular Stories for November 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

One Hundred Years and Beyond: What's Going to Be Hot at AHA 2024

High Lp(a) Linked to ASCVD Risk Even When LDL Cholesterol Is Low

Lp(a) Levels, Still Mostly Genetic, Sometimes Vary Over a Lifetime

Three Common Biomarkers Closely Tied to Women’s 30-Year Risk of CV Events

Lp(a) Still Low Almost 1 Year After Last Olpasiran Injection: OCEAN(a)-DOSE

August 2024 Dispatch for the CV Team

NOW PUBLISHED - LIBerate-HR: Lerodalcibep Lowers LDL More Sharply Than Placebo Over 1 Year

ApoB Can Be High, Risky for ASCVD Even When LDL’s Normal

AV Block Common After Transcatheter Tricuspid Valve Replacement for TR

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Compared With Usual Care, Incorporating Inclisiran Early Cuts LDL

Icosapent Ethyl Lowers CV Risk Across Lp(a) Range: REDUCE-IT

High Lp(a) Levels Harmful in Patients With and Without ASCVD

Increased Lp(a) Ups CV Risk Regardless of hs-CRP Level

Lepodisiran Phase I Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content